Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC